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ARTICLE
The Nuclear Factor kB–Activator Gene PLEKHG5 Is Mutated
in a Form of Autosomal Recessive Lower Motor Neuron Disease
with Childhood Onset
Isabelle Maystadt, Rene´ Rezso¨hazy, Martine Barkats, Sandra Duque, Pascal Vannuffel,
Sophie Remacle, Barbara Lambert, Mustapha Najimi, Etienne Sokal, Arnold Munnich,
Louis Viollet, and Christine Verellen-Dumoulin
Lower motor neuron diseases (LMNDs) include a large spectrum of clinically and genetically heterogeneous disorders.
Studying a large inbred African family, we recently described a novel autosomal recessive LMND variant characterized
by childhood onset, generalized muscle involvement, and severe outcome, and we mapped the disease gene to a 3.9-
cM interval on chromosome 1p36. We identified a homozygous missense mutation (c.1940 TrC [p.647 PherSer]) of the
Pleckstrin homology domain–containing, family G member 5 gene, PLEKHG5. In transiently transfected HEK293 and
MCF10A cell lines, we found that wild-type PLEKHG5 activated the nuclear factor kB (NFkB) signaling pathway and that
both the stability and the intracellular location of mutant PLEKHG5 protein were altered, severely impairing the NFkB
transduction pathway. Moreover, aggregates were observed in transiently transfected NSC34 murine motor neurons
overexpressing the mutant PLEKHG5 protein. Both loss of PLEKHG5 function and aggregate formation may contribute
to neurotoxicity in this novel form of LMND.
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Lower motor neuron diseases (LMNDs) are clinically char-
acterized by progressive paralysis with amyotrophy and
loss of deep tendon reflexes and fasciculations, because of
motor neuron degeneration in the anterior horn of the
spinal cord and the brainstem. Diagnosis is confirmed by
electrophysiological or histological evidence of muscle de-
nervation, with normal or subnormal motor nerve con-
duction velocities and normal sensory potentials. The clas-
sic form of autosomal recessive proximal spinal muscular
atrophy (MIM 253300) is linked to the SMN1 gene,1 but
numerous LMND variants have been described, differing
by localization of motor weakness, mode of inheritance,
and age at onset.2,3 To date, six other causative genes were
reported in pure LMNDs: five with autosomal dominant
inheritance (HSPB8/HSP22 and HSPB1/HSP27 in distal he-
reditary motor neuronopathy type II [d-HMNII {MIM
158590 and 608634}], GARS and BSCL2 in d-HMNV [MIM
600794], and DCTN1 in d-HMNVII [MIM 607641]) and
one with autosomal recessive inheritance (IGHMBP2 in d-
HMNVI, also known as ”spinal muscular atrophy with re-
spiratory distress” [SMARD {MIM 604320}]).4–9 All encode
proteins that are directly or indirectly involved in two
important intracellular pathways: axonal transport and
RNA processing.10,11
Elsewhere, we described a novel clinical variant of au-
tosomal recessive LMND with childhood onset in a large
inbred family originating from Mali.12 Affected individuals
presented with generalized muscle weakness and atrophy
with denervation and normal sensation. Bulbar symptoms
and pyramidal signs were absent. In four of the five af-
fected children, the outcome was severe, with loss of walk-
ing and the need for permanent respiratory assistance be-
fore adulthood. Genetic analyses with the use of a
homozygosity mapping strategy assigned this LMND locus
to a 3.9-cM (or 1.5-Mb) interval on chromosome 1p36,
between loci D1S508 and D1S2633 ( atZ p 3.79 vpmax
at locus D1S253). Here, we report the identification0.00
of the Pleckstrin homology domain–containing, family G
member 5 gene, PLEKHG5 (GenBank accession number
NM_020631), located within the candidate region, which
is mutated in this pedigree.
Subjects and Methods
Clinical Study
Elsewhere, we reported the linkage data on the African family.12
Informed consent was obtained from all family members, and
the study was approved by the ethics committee of the Catholic
University of Louvain.
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Table 1. PLEKHG5 Primers Used for gDNA
and cDNA Sequencing Analyses, Plasmid
Constructions, and Real-Time RT-PCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Genotyping and Mutation Analysis
We isolated genomic DNA (gDNA) from blood samples, using
standard protocols. We performed genotyping for microsatellites
as described elsewhere.12 We used the Primer3 program to design
PCR primers that flanked all exons of candidate genes, on the
basis of the chromosome 1 draft human sequence. Details on
PLEKHG5 primers are given in table 1. We performed direct se-
quencing, using the dideoxy chain-termination method (ABI Big
Dye 3.1) on a 3100 automated sequencer (ABI Prism [Applied
Biosystems]) in accordance with standard procedures and the
manufacturer’s recommendations. The mutation was verified bi-
directionally on gDNA and cDNA. We extracted whole mRNA
from fibroblast cell lines of patients (RNeasy [Qiagen]), and we
obtained cDNA products by RT-PCR, using oligo(dT) and random
hexamers (Transcriptor First Strand cDNA Synthesis Kit [Roche]).
Plasmid Constructions
PLEKHG5 full-ORF expression clones, containing the complete
coding cDNA for isoforms BC042606 or BC015231, were sequence
verified (Deutsches Ressourcenzentrum fu¨r Genomforschung
[RZPD]). To introduce the c.1940 TrC amino acid substitution in
the PLEKHG5 plasmids, we amplified cDNA of the patients with
primers framing the mutation (table 1). We then restricted the
mutated cDNA amplification product and the full-ORF expression
clones with two single-cut endonucleases, BstEII and PflMI (New
England Biolabs). After ligation, we screened for the presence of
the mutated insert, and we verified the absence of additional
mutation by sequencing analysis. pCMVlacZ plasmid was con-
structed by insertion of the Escherichia coli lacZ coding region
into the multiple cloning site of pCMX-PL1.13
Cell Culture and Transfection Conditions
HEK293 cells (human embryonic kidney 293 cells) and MCF10A
cells (human mammary epithelial cells) were maintained at 37C
in a humidified 5% CO2 atmosphere, in Dulbecco’s modified Ea-
gle medium (DMEM) F12 (Invitrogen) supplemented with 5% (for
MCF10A) or 10% (for HEK293) horse serum (Cambrex), 100 IU/
ml penicillin, and 100 mg/ml streptomycin (Sigma). Also added
to the medium for MCF10A cells was 0.1 mg/ml cholera toxin
(Calbiochem), 10 mg/ml insulin (Invitrogen), 0.5 mg/ml hydro-
cortisone (Sigma), and 20 ng/ml human epidermal growth factor
(Invitrogen). Before transfection, exponentially proliferating cells
were trypsinized, and MCF10A cells or5 51.6# 10 2.6# 10
HEK293 cells were plated in each well of a 6-well plate. Twenty-
four hours after plating, cells were transfected using 3 ml of Fugene
6 (Roche) in accordance with the manufacturer’s instructions. For
luciferase-reporter gene assays and real-time RT-PCR analyses, 0.5
mg of the expression vectors was transfected together with 1 mg
of the reporter plasmid (nuclear factor kB [NFkB] cis-reporting
system [Stratagene]) and with 20 ng of constitutive reporter plas-
mid (pCMVlacZ) for luciferase activity normalization. Expression
vectors were replaced by 50 ng of pFC-MEKK (Stratagene) and 0.5
mg of carrier DNA (pCat), to provide a positive control for NFkB
activation. For western-blot analyses and immunofluorescence
studies, cells were transfected with 1.5 mg of expression vector
DNA.
NSC34 cells (a mouse embryonic spinal cord–neuroblastoma
cell line with a motor neuron phenotype, kindly provided by Dr.
Neil Cashman, University of Toronto14) were cultured at 37C
under 5% CO2 and 95% air in DMEM supplemented with 10%
fetal calf serum. NSC34 cells in a 24-well plate were transfected
with either the wild-type or the mutant PLEKHG5 plasmids with
use of Lipofectamine (Invitrogen). The transfection efficacy was
controlled using cotransfection with a green fluorescent protein
(GFP)–expressing plasmid.
Enzymatic Assays
Cells were harvested 48 h after transfection. Lysis and enzymatic
activity dosages were performed with the b-Gal Reporter Gene
Assay (chemiluminescent) kit (Roche) and the Luciferase Reporter
Gene assay (high-sensitivity) kit (Roche).
Gene-Expression Analysis by Quantitative RT-PCR
Total RNA was isolated 48 h after transfection and was purified
using the Trizol procedure (Invitrogen) in accordance with the
manufacturer’s instructions. cDNA was transcribed from 3 mg of
total RNA by use of random hexamers and M-MLV Reverse Tran-
scriptase (Invitrogen), in the presence of RNase inhibitor (Pro-
mega). Quantitative real-time RT-PCR amplification was per-
formed on cDNA by use of the qPCR Master Mix Plus for SYBR
Green I (Eurogentec) in the presence of PLEKHG5-specific primers
(Eurogentec) (table 1). The measurement of the b2 microglobulin
gene provided an amplification control that allowed PLEKHG5
expression to be normalized. Each reaction was performed in trip-
licate, by use of an MX3000P Real-Time PCR System (Stratagene).
Synthesis of Polyclonal Antibody to PLEKHG5
Polyclonal antibodies to PLEKHG5 were obtained by immuni-
zation of two rabbits with two synthesized specific peptides (NH2-
CYLRVKAPAKPGDEG-CONH2 and NH2-CKVDIYLDQSNTPLSL-
CONH2) and were purified on a sepharose column (Covalab).
High reactivity of immunopurified antibodies was confirmed by
ELISA.
Western-Blot Analysis
Proteins were harvested 48 h after transfection. Cells were washed
three times with ice-cold PBS and then were lysed in 0.32 M
sucrose or in lysis buffer (10 mM Hepes [pH 7.8], 10 mM KCl, 2
mM MgCl2, 0.1 mM EDTA, and 1 mM dithiothreitol) and 10%
Nonidet P40 (Sigma), with the addition of the Protease Inhibitors
cocktail (Roche). Cell extracts were boiled for 5 min in Laemmli
buffer and were submitted to a 7.5% SDS-PAGE. Proteins were
electroblotted onto nitrocellulose membranes. After electro-
blotting, membranes were treated with 5% dry milk in TBS buffer
(50 mM Tris [pH 8.1] and 150 mM NaCl) containing 0.05%
Tween-20, for 1 h at room temperature, and then were hybridized
overnight at 4C with anti-PLEKHG5 antibodies (1:1,000) diluted
in blocking solution. The antigen-antibody complexes were re-
vealed by secondary incubation with horseradish peroxidase–cou-
pled goat anti-rabbit immunoglobulin G antibodies (1:10,000
[Sigma]). Immunoreactive proteins were visualized using en-
hanced chemiluminescence reagents (Perkin Elmer). Hybridiza-
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Figure 1. Physical map of the locus associated with generalized LMND, structure of PLEKHG5, and location of the mutation identified
in the African family. a, Location and transcriptional direction of the 27 sequenced genes (UCSC Genome Browser). b, Structure of
PLEKHG5 (UCSC Genome Browser). The five isoforms annotated by NCBI genome browser are in black, and the two Mammalian Gene
Collection Full ORF mRNAs used for plasmid constructions are in gray. The coding exons are shown as vertical bars, illustrating their
approximate size and position. The position of the initiation codon (ATG) at nucleotide 1 is indicated in red, and the position of
the stop codon (TGA) is indicated in green. The 5′ and 3′ UTRs are shown as shorter vertical bars. Locations of the PH and RhoGEF
domains are also shown (Pfam). The identified homozygous mutation is located in the PH domain (red arrow). c, Electrophoregram of
affected individuals compared with a control, showing the homozygous c.1940 TrC (p.647 PherSer) mutation (GenBank accession
number NM_020631.2). WTp wild type. d, Phenylalaline at position 647 (boxed in red) highly conserved across species: Homo sapiens,
Pan troglodytes, Mus musculus, Rattus norvegicus, Danio rerio, and Caenorhabditis elegans (UCSC Genome Browser). e, Comparison of the
PH domain of PLEKHG5 with the PH domain consensus sequence (PH-cons). In this sequence, the eight consensus residues are indicated
in capital letters, including the mutant phenylalanine (boxed in red) (Pfam). f, Predictive three-dimensional structure of PLEKHG5
(ModBase). The RhoGEF domain has an a-helical structure, and the PH domain consists of seven b-sheets, followed by a C-terminal
amphipathic helix. The mutation occurs in the area of the b5/b6 loop of the PH domain, which may be part of the phospholipids
binding site.15
tion with b-actin antibody (1:1,000 [Sigma]) was performed as a
control.
Immunocytochemistry and Microscopy
Transfected HEK293 and MCF10A cells were fixed in 4% formal-
dehyde 48 h after transfection. We permeabilized cells with 1%
Triton X-100 in PBS for 15 min and blocked aspecific fixation
sites in 5% nonfat milk for 2 h at room temperature. Cells were
incubated with anti-PLEKHG5 polyclonal antibodies (1:100) for
1 h and then with fluorescein isothiocyanate–conjugated goat
anti-rabbit antibody (1:1,000 [Sigma]) for an additional 1 h. Cells
were examined using a Zeiss Axioplan 2 imaging microscope
equipped with ISIS 3 software (MetaSystem).
Transfected NSC34 murine cells were treated for PLEKGH5 im-
munofluorescence with the polyclonal anti-PLEKGH5 antibody
(1:100) coupled with diamidino-4′,6-phenylindole-2 dichlorhy-
drate staining of the nuclei. Cells were incubated with the pri-
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Figure 2. Expression of PLEKHG5 in the human nervous system.
PLEKHG5 expression was evaluated in several human nervous tis-
sues by real-time quantitative RT-PCR. All reactions were performed
in triplicate, and PLEKHG5 expression was normalized according
to b2 microglobulin expression. Results were expressed as ampli-
fication rates in comparison with PLEKHG5 expression in untrans-
fected HEK293 cell line. PLEKHG5 transcripts were detected in all
studied tissues, supporting its ubiquitous expression pattern in
the human nervous system, with a predominance in peripheral
nerve and spinal cord. Sm p skeleton muscle; Br p brain; Sc p
spinal cord; Pn p peripheral nerve.
mary anti-PLEKHG5 antibody (1:100) overnight, followed by a
rhodamine (A-594)–conjugated anti-rabbit secondary antibody
(1:800 [Invitrogen]) for an additional 1 h. PLEKGH5- and GFP-
coexpressing cells were observed using confocal analysis (Leica).
Statistical Analysis
P values were calculated by Welch’s t test, by use of R software
(version 2.3.0.).
Results
We sequenced the 25 candidate and predicted genes lo-
cated in the 3.9-cM mapped interval on chromosome
1p36 (NPHP4, KCNAB2, CHD5, RPL22, RNF207, C1orf188,
ICMT, C1orf211, HES3, GPR153, ACOT7, HES2, ESPN,
TNFRSF25, PLEKHG5, NOL9, TAS1R1, HKR3, KLHL21,
PHF13, THAP3, DNAJC11, CAMTA1, AK098599, and
AK128074), as well as two additional candidate genes
known to cause Charcot-Marie-Tooth disease (CMT) and
located very close to this chromosomal region (MFN2 and
KIF1Bb) (fig. 1a). In the five affected members of the Mal-
ian family, we found a homozygous mutation (c.1940
TrC) resulting in an amino acid substitution (p.647
PherSer) in the pleckstrin homology (PH) domain of the
PLEKHG5 protein (fig. 1c). The mutation was not detected
in 300 healthy controls (600 chromosomes), of whom 250
originated from Mali (500 chromosomes). The mutant
phenylalanine is highly conserved across species and is a
canonical amino acid residue of the PH consensus se-
quence (fig. 1d and 1e). We then screened PLEKHG5 in a
sample of four unlinked families and 16 isolated patients
with a close phenotype, but we identified no additional
mutations.
PLEKHG5 spans 53,917 bp on human chromosome 1
and codes for a member of the Dbl protein family that
shares a PH domain and a guanine nucleotide exchange
factor for Rho protein (RhoGEF) domain.16 Interestingly,
it has been suggested elsewhere that the PLEKHG5 protein
has an NFkB-activating function.17 Five mRNA isoforms
annotated by National Center for Biotechnology Infor-
mation (NCBI) genome browser and two Mammalian
Gene Collection Full ORF mRNAs have been reported to
code for proteins that mainly differ by their N-terminal end
(GenBank accession numbers NM_020631, NM_198681,
NM_001042663, NM_001042664, NM_001042665,
BC042606, and BC015231) (fig. 1b). According to micro-
array databases (UniGene, Expression Profile Viewer),
PLEKHG5 is ubiquitously expressed, but predominantly
in the peripheral nervous system and brain. Using western
blotting and immunofluorescence, we failed to detect en-
dogenous PLEKHG5 protein in various human cells (fi-
broblastic cell lines, lymphoblastoid cell lines, cultured
amniocytes, and cultured primary hepatocytes) (data not
shown). However, using real-time quantitative RT-PCR, we
confirmed the ubiquitous expression of PLEKHG5 in the
human nervous system, with a predominance in periph-
eral nerve and spinal cord (fig. 2).
To further investigate the impact of the c.1940 TrC
mutation, two isoforms of PLEKHG5 (BC042606 and
BC015231) (fig. 1b) were transfected in HEK293 and
MCF10A cell lines. The wild-type PLEKHG5 protein was
not visualized by western blotting or immunofluorescence
before transfection. By contrast, after transfection of
expression vectors encoding wild-type BC015231 and
BC042606 isoforms, we detected protein fragments of 130
and 150 kDa in cell lysates, using polyclonal rabbit anti-
PLEKHG5 antibodies (fig. 3a). In addition, immunoflu-
orescence analysis revealed that wild-type PLEKHG5 pro-
teins were diffusely localized in cytoplasm (fig. 3b). On
the contrary, in cells transfected with the corresponding
c.1940 TrC mutant constructs, mutant PLEKHG5 proteins
were consistently undetectable by western blotting, sug-
gesting an instability of the mutant variants (fig. 3a). By
immunofluorescence, mutant PLEKHG5 proteins were not
detected with a classic exposure time (0.04 s). However, a
light, diffuse cytoplasmic signal could be detected after a
longer exposure time (0.34 s) (fig. 3b).
The two isoforms of PLEKHG5 were then tested for their
ability to activate the NFkB pathway. HEK293 and
MCF10A cell lines were transfected with a luciferase-
reporter gene responsive to NFkB, together with expres-
sion vectors encoding either wild-type or c.1940 TrC mu-
tated PLEKHG5 cDNAs. Although the PLEKHG5 transcript
was barely detected in untransfected control cells by use
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Figure 3. Analysis of wild-type (WT) and mutant PLEKHG5 protein expression in untransfected (untransf) and transiently transfected
HEK293, MCF10A, and NSC34 cells. a, Analysis by western blotting of PLEKHG5 protein expression in HEK293 cells. PLEKHG5 protein
was not detectable in untransfected cells. The 130-kDa and 150-kDa bands were detected in cells overexpressing the BC015231 and
BC042606 wild-type isoforms. In contrast, no similar bands were observed in cells transfected with the mutant variants. Similar results
were found after distinct protein extraction methods (with 0.32 M sucrose or lysis buffer A; see the “Subjects and Methods” section)
and in both HEK293 and MCF10A cells. b, Immunofluorescence assays of PLEKHG5 protein expression in HEK293 and MCF10A cells. b1,
There was an absence of signal in untransfected cells, even with a long exposure time (0.34 s). b2, With an exposure time of 0.04 s,
cells transfected with wild-type PLEKHG5 showed a diffuse cytoplasmic distribution of PLEKHG5 protein. b3, In cells transfected with
the mutant constructs, no protein was visualized with an identical exposure time (0.04 s). b4, Increased exposure time (0.34 s) revealed
a weak signal in the nucleus and the cytoplasm. c, Analysis by western blotting of PLEKHG5 protein expression in NSC34 cells. Wild-
type PLEKHG5 protein was not detectable in untransfected cells. The 150-kDa band was detected in cells overexpressing the BC042606
wild-type isoform. In contrast, the band intensity was clearly decreased in cells transfected with the BC042606 mutant variant. d,
Immunofluorescence assays of PLEKHG5 protein expression in NSC34 cells. The transfection efficacy was controlled using cotransfection
with a GFP-expressing plasmid. d1, There was an absence of signal in GFP-negative nontransfected cells. d2, Cells transfected with the
wild-type PLEKHG5 plasmid showed a diffuse cytoplasmic distribution of the PLEKHG5 protein. d3 and d4, Presence of large immuno-
reactive aggregates (white arrows) in the soma of NSC34 motor neurons transfected with the mutant PLEKHG5 plasmids.
of real-time quantitative RT-PCR, its abundance increased
up to 1,000-fold after transfection in cells transfected with
either wild-type or mutant PLEKHG5 variants (fig. 4). Con-
sistently, the luciferase activity was more than sixfold
higher in the wild-type PLEKHG5–transfected cells than
in the control cells. By contrast, induction of the luciferase
activity was markedly reduced in cells transfected with the
mutant isoforms (fig. 5a), therefore demonstrating that
the amino acid substitution severely impaired PLEKHG5
ability to activate the NFkB pathway. This loss of activity
clearly reflects, at least in part, the instability of the mu-
tant protein.
Finally, we transiently transfected murine motor neu-
ronal NSC34 cells with the two wild-type BC015231 and
BC042606 isoforms and the corresponding mutant con-
structs. Western-blotting experiments confirmed the in-
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Figure 4. Quantification, by real-time RT-PCR, of PLEKHG5 ex-
pression levels in untransfected and transfected HEK293 and
MCF10A cells. At 48 h after transfection, the cells were harvested
and were analyzed by real-time RT-PCR for PLEKHG5 mRNA. The
fluorescence was measured in every PCR cycle and was proportional
to the accumulation of PCR product. Endogenous expression of
PLEKHG5 was detected in untransfected control cells but was mark-
edly increased in transfected cells (up to 1,000-fold, estimated by
DDCt method). Overexpression of wild-type (WT) and mutated
PLEKHG5 in transfected cells was similar. Triplicate analyses were
performed for each sample.
stability of the mutant PLEKHG5 proteins, which accu-
mulated to much lower level than that of the wild-type
proteins (fig. 3c). Detection of the mutant PLEKHG5 pro-
teins by immunofluorescence revealed formation of ag-
gregates in the motor neuron somas close to the nucleus
in the majority (60%–70%) of the transfected cells (fig.
3d). This was observed neither in NSC34 cells transfected
with the wild-type counterparts nor in nontransfected
cells.
In conclusion, transfection experiments using PLEKHG5
variants in distinct cellular models supported instability
and loss of NFkB-activating function of the mutant
PLEKHG5 proteins and revealed their involvement in ag-
gregate formation in transfected murine motor neuron
cells.
Discussion
The mechanism by which the mutation in the PH domain
of PLEKHG5 leads to an autosomal recessive, generalized
LMND is unclear. PH domains are protein modules of∼100
aa, found in a wide range of eukaryotic proteins, many of
which are involved in cell signaling and cytoskeletal reg-
ulation. They play a membrane-anchoring function be-
cause of their ability to bind to phosphoinositides.18 In
Dbl-family proteins, including PLEKHG5, PH domains
also independently contribute to the allosteric regulation
of the RhoGEF domain. This latter domain activates
GTPases by stimulating the exchange of GDP to GTP,
thereby initiating various signaling mechanisms that reg-
ulate neuronal shape and plasticity, dendrite growth, syn-
apse formation, and neuronal survival.19–22 Recent exper-
iments show that mutations in the PH domain, impairing
phosphoinositide binding, do not systematically affect
protein subcellular localization. However, in all cases,
these mutations significantly reduce the guanine nucle-
otide exchange activity of the Dbl proteins.23
Two proteins sharing a PH domain or a PH/RhoGEF do-
main have already been shown to account for human neu-
rodegenerative diseases: Dynamin 2 (encoded by DNM2)
and alsin (encoded by ALS2). Mutations of the PH domain
of Dynamin 2 have been reported in CMT, dominant in-
termediate B (DI-CMTB [MIM 606482]), whereas muta-
tions outside the PH domain are responsible for a domi-
nant myopathic phenotype (centronuclear myopathy
[MIM 160150]), suggesting that the PH domain could be
specifically involved in motor neuron maintenance.24,25
Mutations in ALS2 have been described in three overlap-
ping autosomal recessive diseases: juvenile amyotrophic
lateral sclerosis (ALS2 [MIM 205100]), infantile-onset as-
cending spastic paraplegia (IAHSP [MIM 607225]), and ju-
venile primary lateral sclerosis (PLS [MIM 606353]).26–32
The alsin protein is composed of three guanine nucleotide
exchange factor domains, which result in Ran, Rho/Rac1,
and Rab5 guanine nucleotide exchange activities, in-
volved in motor neuron maintenance, axonal transport,
and neurite outgrowth.10,11 The crucial role of the PH/
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Figure 5. Comparison between wild-type (WT) and mutated PLEKHG5 activity on the NFkB signaling pathway. a, Reporter construct
consisting of the luciferase gene placed under control of a promoter containing the consensus NFkB binding sites (Stratagene), transfected
in HEK293 or MCF10A cells alone (Control), in combination with expression vectors for wild-type and mutated PLEKHG5 proteins (BC015231
and BC042606), or in combination with expression vector for a positive control of NFkB activation (pFC-MEKK). Values are expressed
as fold activation over transfection of the reporter plasmid alone. Bars indicate the SD of five independent experiments. The differences
between wild-type and mutated PLEKHG5 are statistically significant according to Welch’s t test. b, Schematic representation of the
plasmid constructions (see the “Subjects and Methods” section). Untransf. p untransfected. PCMV p CMV promoter; TATA p TATA box.
RhoGEF domain for the alsin-mediated neuroprotection
against the toxic effect of the mutant form of SOD1 has
recently been demonstrated.33,34 Similar to PLEKHG5, en-
dogenous alsin is a low-abundance protein enriched in
neural tissues.35 The reported mutations of the ALS2 gene
are rarely located in the PH domain. However, all but one
of the causative mutations generate alsin protein trun-
cation, often leading to the loss of the PH domain. Except
for the recently reported missense G540E mutation, a loss-
of-function mechanism was attributed to the causative
homozygous mutations in the ALS2 gene. Indeed, when
expressed in cultured HEK293 cells, most of the disease-
associated mutant forms are unstable and are rapidly de-
graded by the proteasome, as observed with mutant
PLEKHG5.35
The Rho family of GTPases are known to activate the
NFkB signaling pathway.36,37 Here, we confirm the NFkB-
activating function of PLEKHG5. The NFkB signaling path-
way has not been found to be directly involved in human
motor neuronopathies. However, its neuronal antiapop-
totic role has been documented in various cellular models,
and several studies showed that inhibition of the NFkB
pathway promoted apoptosis in neurons.38–43 Moreover,
down-regulation of NFkB activity has recently been ob-
served in the expanded polyglutamine protein-expressing
neuro-2a cells, suggesting that this pathway could be in-
volved in the pathogenesis of polyglutamine-degenerative
disorders, including Kennedy disease (MIM 313200), a spi-
nobulbar muscular atrophy.44 Therefore, considering its
wide CNS expression pattern and its NFkB-stimulating ac-
tivity, PLEKHG5 might play a role in neuronal mainte-
nance. Indeed, a mutation in the PH domain leading to
the loss of NFkB activation could fail to protect neurons
against apoptosis and could compromise the neuronal
survival.
Finally, we showed that mutant PLEKHG5 variants
formed aggregates in transfected NSC34 murine motor
neurons. Interestingly, aggregates were never observed in
wild-type–transfected NSC34 cells, and formation of mu-
tant PLEKHG5 aggregates appeared to be specific to the
neuronal cell line, because they were not observed in
transfected HEK293 and MCF10A cells. This last finding
argues against the hypothesis of an artifact of overex-
pression.45 Animal models or human postmortem histo-
logical studies would be useful for evaluating whether this
observation in vitro is correlated with intracellular inclu-
sions in vivo. Although the neurotoxic or neuroprotective
effect of aggregates is still debated, abnormal aggregation
is a common feature in several neurodegenerative diseases,
including motor neuron diseases.45–49 In particular, protein
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aggregation has been recognized as a characteristic change
in degenerating motor neurons of amyotrophic lateral
sclerosis (MIM 105400) with mutant SOD1.50 Moreover,
transfection experiments revealed abnormal aggregation
of various mutated proteins involved in autosomal dom-
inant distal hereditary motor neuropathies, such as the
small heat-shock proteins 1 and 8 (HSPB1 and HSPB8),
the seipin protein (Bscl2), and the dynactin protein
(DCTN1).8,9,51–53 In these examples, there is increasing evi-
dence that the misfolded protein and aggregate structures
lead to a dominant pathological phenotype by a toxic
gain-of-function mechanism or by the combination of
both loss of function and toxic gain of function.9,51,53–56
Conversely, specific aggregation of mutant proteins in-
volved in autosomal recessive LMNDs has not yet been
reported.
Whether PLEKHG5 is directly or indirectly involved in
RNA processing or axonal transport in motor neuron, as
postulated for the other LMND-causative genes, remains
to be further explored. As already described in neurode-
generative diseases with aggregate accumulation, mutant
PLEKHG5 could generate toxic interaction with various
intracellular partners, including specific components of
the axonal cytoskeleton, leading to the disruption of the
anterograde transport pathway in motor neurons.7,8,11,33,
51,56–60
In conclusion, we have demonstrated that a form of
LMND with childhood onset is caused by a homozygous
mutation (c.1940 TrC [p.647 PherSer]) in the PLEKHG5
gene. This mutation caused protein instability, impaired
the ability of PLEKHG5 to activate the NFkB pathway in
transfected HEK293 and MCF10A cell lines, and eventu-
ally led to aggregate formation in a transfected murine
NSC34 motor neuron cell line. The observation of a mu-
tation of the PLEKHG5 gene in a motor neuron degen-
erative disorder suggests that the RhoGEF-mediated NFkB
signaling pathway plays an important function in motor
neuron maintenance and could be involved in other hu-
man neuronopathies as well.
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